Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 15/20 | 0.45 |
| ▸ | CTRB1 | P17538 | 5/20 | 0.44 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
| ▸ | LIPE | Q05469 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6806821 | 0.93 | ELANE (0.47) | ELANECTRB1HCRTR1 | |
| SCHEMBL6806792 | 0.90 | ELANE (0.43) | ELANECTRB1LIPE | |
| SCHEMBL6806545 | 0.89 | ELANE (0.43) | ELANECTRB1 | |
| SCHEMBL6504209 | 0.89 | CTRB1 (0.46) | ELANECTRB1HCRTR1 | |
| SCHEMBL6506622 | 0.89 | ELANE (0.46) | ELANECTRB1TACR1LIPE | |
| SCHEMBL6802038 | 0.89 | ELANE (0.48) | ELANECTRB1HCRTR1 | |
| SCHEMBL6805565 | 0.88 | ELANE (0.43) | ELANECTRB1TACR1 | |
| SCHEMBL6497830 | 0.88 | LMNA (0.45) | ELANECTRB1TACR1 | |
| SCHEMBL6809911 | 0.88 | ELANE (0.44) | ELANECTRB1 | |
| SCHEMBL6806153 | 0.87 | ELANE (0.39) | ELANECTRB1TACR1LIPEHCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6380189-B1 | FOR TREATING HERPES-RELATED DISORDERS | G.D. SEARLE & CO. | 2002-04-30 | — | — | US | claimed |
| EP-0828721-B1 | 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF VIRAL INFECTIONS | SEARLE & CO (US) | 2001-11-14 | — | — | EP | claimed |
| US-6683077-B2 | 4H-3,1-BENZOXAZIN-4-ONE COMPOUNDS OF GIVEN FORMULA; HERPES INFECTIONS; ASSEMBLIN PROTEASE INHIBITORS | G.D. SEARLE & CO. | 2004-01-27 | — | — | US | disclosed |
| US-20030022895-A1 | 2-Amino-benzoxazinones for the treatment of viral infections | G.D. SEARLE & CO. | 2003-01-30 | — | — | US | disclosed |
| US-6380189-B1 | FOR TREATING HERPES-RELATED DISORDERS | G.D. SEARLE & CO. | 2002-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022895-A1 | 2-Amino-benzoxazinones for the treatment of viral infections | IFNAR1, IL4I1, HAX1 | ELANE 2176/4885CTRB1 2628/4885TACR1 1837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.